Monday 12 October 2026
Export all AMGN data to Excel Powerpack
Amgen Inc.
AMGN Healthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.
414.87
7.43
+1.82%
Follow AMGN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
21.66 | 22.84 | 24.30 | 22.33 |
P/S ratio |
4.22 | 4.79 | 5.10 | 5.13 | |
P/FCF ratio |
13.67 | 22.97 | 23.28 | 20.07 | |
P/Operating CF |
32.41 | 109.85 | 86.80 | 48.86 | |
P/B ratio |
15.78 | 20.34 | 20.67 | 16.73 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.48 | 6.03 | 6.32 | 6.27 | |
EV/EBITDA |
12.85 | 14.34 | 14.83 | 14.48 | |
EV/Operating CF |
15.01 | 22.25 | 21.87 | 19.14 | |
EV/FCF |
17.74 | 28.90 | 28.82 | 24.52 | |
Quick Ratio |
0.82 | 0.73 | 0.85 | 0.95 | |
Current Ratio |
1.28 | 1.14 | 1.26 | 1.37 | |
Net Debt/EBITDA |
10.66 | 11.81 | 11.97 | 9.36 | |
Debt/Assets |
60.56% | 60.28% | 61.97% | 59.92% | |
Debt/Equity |
5.67 | 6.31 | 6.24 | 4.90 | |
Asset Turnover |
0.40 | 0.40 | 0.41 | 0.42 | |
Operating CF/Net income |
1.46 | 1.20 | 1.20 | 1.69 | |
Capex/Depreciation |
(0.26) | (0.57) | (0.64) | (0.46) | |
Interest Coverage |
3.69 | 4.17 | 4.06 | 5.22 | |
Research and Development Expense of Revenue |
19.88% | 21.71% | 19.95% | 18.58% | |
Selling, General and Administrative Expense of Revenue |
18.00% | 19.79% | 18.59% | 17.36% | |
Intangible Assets out of Total Assets |
0.46 | 0.45 | 0.43 | 0.41 | |
Share Based Compensation of Revenue |
1.33% | 1.27% | 0.87% | 1.64% | |
Graham Net Nets |
(0.35) | (0.30) | (0.27) | (0.25) | |
Graham Number |
72.40 | 72.03 | 74.46 | 88.88 | |
Earnings Yield |
4.62% | 4.38% | 4.12% | 4.48% | |
Free Cash Flow Yield |
7.31% | 4.35% | 4.30% | 4.98% | |
Revenue per Share |
17.76 | 18.34 | 15.96 | 18.62 | |
Operating CF per Share |
8.71 | 2.98 | 4.05 | 7.41 | |
Capex per Share |
(0.81) | (1.19) | (1.32) | (0.95) | |
Free Cash Flow per Share |
7.90 | 1.79 | 2.74 | 6.46 | |
Cash per Share |
17.56 | 16.97 | 22.29 | 25.91 | |
Shareholders Equity per Share |
17.88 | 16.09 | 17.02 | 21.64 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.88 | 16.09 | 17.02 | 21.64 | |
Free Cash Flow |
4,248.00 | 961.00 | 1,477.00 | 3,489.00 | |
Working Capital |
6,094.00 | 3,568.00 | 6,520.00 | 9,459.00 | |
Capital Expenditures |
(436.00) | (642.00) | (712.00) | (513.00) | |
Net Current Asset Value |
(52,637.00) | (52,871.00) | (51,839.00) | (48,990.00) | |
EV/EBIT |
22.72 | 24.40 | 22.26 | 20.90 | |
Capex to Sales |
0.05 | 0.07 | 0.08 | 0.05 | |
Price to Operating Income |
17.51 | 19.39 | 17.98 | 17.11 | |
| Other line items | |||||
Average Receivables |
7,903.50 | 8,176.00 | 8,635.00 | 9,464.00 | |
Average Payables |
2,492.50 | 2,137.50 | 2,670.50 | 2,937.50 | |
Average Inventory |
6,854.00 | 6,611.50 | 6,457.50 | 6,401.50 | |
Average Assets |
90,512.00 | 91,212.50 | 90,935.50 | 91,768.00 | |
Average Common Equity |
8,573.00 | 7,267.50 | 7,698.50 | 9,558.00 |
Columns are period end dates